Clinical impact of implementing the recommendations of AAPM task group 43 on permanent prostate brachytherapy using 125I

International Journal of Radiation Oncology Biology Physics

Volumn 40, Issue 5, 1998, Pages 1237-1241

  Bice Jr , William S ^a,b   Prestidge, Bradley R ^a,b   Prete, James J ^a,b   Dubois, Donald F ^a,b  

^a WILFORD HALL MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

125Iodine; Brachytherapy; Dosimetry; Prostate

Indexed keywords

IODINE 125;

ANISOTROPY; ARTICLE; BRACHYTHERAPY; CLINICAL ARTICLE; CLINICAL PROTOCOL; COMPUTER ASSISTED TOMOGRAPHY; DOSIMETRY; HEALTH CARE QUALITY; HUMAN; INTERSTITIAL RADIATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE; TRANSRECTAL ULTRASONOGRAPHY;

BRACHYTHERAPY; HUMANS; IODINE RADIOISOTOPES; MALE; PRACTICE GUIDELINES; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; SOCIETIES, SCIENTIFIC;

EID: 0032521001     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(97)00949-8     Document Type: Article

References (16)

1. Interstitial brachytherapy Physical, biological and clinical considerations . 1990;Raven Press, New York.
2. Nath R., Anderson L. L., Luxton G., Weaver K. A., Williamson J. F., Meigooni A. S. Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. Med. Phys. 22:1995;209-234.
3. Blasko J. C. Transperineal percutaneous iodine-125 implantation for prostatic carcinoma using transrectal ultrasound and template guidance. Endocuriether. Hypertherm. Oncol. 3:1987;131-139.
4. 125I implantation for stage T1/T2 prostatic carcinoma. J. Urol. 154:1995;1096-1099.
5. 103Pd for the treatment of early stage prostate cancer. Atlas Urol. Clin. North Am. 2:1994;113-125.
6. Prestidge B. R., Hoak D. C., Grimm P. D., Ragde H., Cavanagh W., Blasko J. C. Posttreatment biopsy results following interstitial brachytherapy in early-stage prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 37:1997;31-39.
7. Priestly J. B., Beyer D. C. Guided brachytherapy for treatment of confined prostate cancer. Urology. 40:1992;27-32.
8. 125iodine prostate implants. J. Urol. 146:1991;90-95.
9. 125I prostate implantation. Int. J. Radiat. Oncol. Biol. Phys. 30:1994;405-409.
10. Wallner K., Roy J., Harrison L. Tumor control and morbidity following transperineal iodine-125 implantation for Stage T1/T2 prostatic carcinoma. J. Clin. Oncol. 14:1996;449-453.
11. Meisberger L. L., Keller R. J., Shalek R. J. The effective attenuation in water of the gamma rays of gold 198, iridium 192, cesium 137, radium 226, and cobalt 60. Radiology. 90:1968;953-957.
12. Dale R. G. Some theoretical derivations relating to the tissue dosimetry of brachytherapy nuclides, with particular reference to iodine-125. Med. Phys. 10:1983;176-183.
13. 125I seeds. Med. Phys. 3:1976;48-51.
14. Saw C. B., Suntharalingam N. Quantitative assessment of interstitial implants. Int. J. Radiat. Oncol. Biol. Phys. 20:1991;135-139.
15. 125I transperineal prostate seed implants on commercial treatment planning systems. Int. J. Radiat. Oncol. Biol. Phys. 37:1997;737-741.
16. Prestidge B. R., Prete J. J., Buchholz T. A., Bice W. S. Results of a permanent prostate brachytherapy patterns of care analysis. Int. J. Radiat. Oncol. Biol. Phys. 40:1998;461-465.